Julia Medeiros Sorrentino

Julia Medeiros Sorrentino

Auto-generated profile, based on publicly available information

Julia Medeiros Sorrentino

Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2024 in Biomedical Chromatography
Verified
Journal Article
Closed access
RSRafaela Martins Sponchiado
Rafaela Martins Sponchiado
JSJúlia Sorrentino
Júlia Sorrentino
LCLeticia Malgarim Cordenonsi
Leticia Malgarim Cordenonsi
AFAlexandre Meneghello Fuentefria
Alexandre Meneghello Fuentefria
ADAlexandro Dallegrave
Alexandro Dallegrave
CGCássia Virginia Garcia
Cássia Virginia Garcia

7 June 2025 in Separation Science Plus
Verified
Journal Article
Open access
RSRafaela Martins Sponchiado
Rafaela Martins Sponchiado
BCBrendha Lang Camboim
Brendha Lang Camboim
JSJulia Medeiros Sorrentino
Julia Medeiros Sorrentino
LCLeticia Malgarim Cordenonsi
Leticia Malgarim Cordenonsi
ADAlexsandro Dallegrave
Alexsandro Dallegrave
CGCássia Virginia Garcia
Cássia Virginia Garcia
The focus of the present study was the monitoring of ambrisentan (AMB) in vitro biotransformation by two fungal cultures: Aspegillus niger ATCC 9029 and Penicillium mineoluteum URM 6889. This drug is a selective endothelin Type A, receptor antagonist, used for pulmonary arterial hypertension. In vitro metabolism study was carried out by incubating AMB with fungus and culture medium under controlled conditions for further analysis of metabolites formed through an alternative method. After incubation for 240 hours with A. niger , drug was metabolized into two substances: one is known (M2) with 3.75 min retention time and another unknown (M3) at 4.37 min retention time in high performance liquid chromatography–diode array detector method (HPLC‐DAD). Structures were suggested by using ultra high performance liquid chromatography/quadrupole time‐of‐flight mass spectrometry (UHPLC‐QTOF/MS) method. When drug was submitted to biotransformation with P. mineoluteum , no different signals than those formed in the controls were observed, demonstrating it is not adequate to the purpose. The findings indicate that fungi A. niger could be used to generate mammalian metabolites of AMB on a small scale and can also be used as reference standard for identification and analytical tests of mammalian metabolites of this drug.

18 July 2025 in Drug Analytical Research
Verified
Journal Article
Open access
PDF file
JSJulia Medeiros Sorrentino
Julia Medeiros Sorrentino
RSRafaela Martins Sponchiado
Rafaela Martins Sponchiado
FBFábio De Souza Barbosa
Fábio De Souza Barbosa
JMJoanna Wittckind Manoel
Joanna Wittckind Manoel
ISIlana Saute Glock Slub
Ilana Saute Glock Slub
MSMartin Steppe
Martin Steppe
Filamentous fungi exhibit a complex morphology and can display various shapes depending on the species and environment. These characteristics serve as advantages in biotransformation studies by allowing substances to undergo processes that lead to the production of both existing metabolites and new compounds with potential pharmacological activity. In this regard, the biotransformation of drugs using microorganisms emerges as an economical and ecologically viable strategy for modifying the structures of biologically active compounds, studying the metabolism of molecules, and eliminating or reducing their toxicity. Therefore, the objective of this study was to investigate the biotransformation capacity of the drug nitazoxanide by the endophytic fungi Aspergillus niger ATCC 9029 and Cunninghamella elegans ATCC 9245. High-performance liquid chromatography was employed to monitor metabolite formation, while ultra-high-performance liquid chromatography coupled with sequential mass spectrometry (UHPLC-QTOF/MS) was utilized to identify these metabolites. After an incubation period of 240 hours, nitazoxanide was transformed into two metabolites by C. elegans. A. niger demonstrated a consumption rate of 94.17% for nitazoxanide, with two additional metabolites identified. This study highlights the potential of using fungi both as a model for metabolism and as a means of producing metabolites on a larger scale, while also identifying a new and significant area of application for the biotransformation approaches involving filamentous fungi.